MindWalk Holdings (HYFT) Cash from Operations (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Cash from Operations of 1756650.5 for Q2 2026, down 119.28% year-over-year from 9112735.94 in Q2 2025, and up 17.97% quarter-over-quarter from 2141533.15 in Q1 2026.
MindWalk Holdings (HYFT) Cash from Operations (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Cash from Operations for 4 consecutive years, with 1756650.5 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 119.28% year-over-year to 1756650.5; the TTM figure through Apr 2026 stood at 9033265.99 (down 95.39% YoY), while the FY2026 annual figure was 9091833.57, down 97.58% from the prior year.
- Cash from Operations rose to 1756650.5 in Q2 2026 per HYFT's latest filing, from 2141533.15 in the prior quarter.
- Across five years, Cash from Operations topped out at 13274.89 in Q4 2023 and bottomed at 3066159.59 in Q3 2025.
- Historically, Cash from Operations has averaged 1449478.04 across 4 years, with a median of 1487307.29 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 70.95% in 2024 and fell as far as 12278.68% in 2024.
- MindWalk Holdings' Cash from Operations stood at 13274.89 in 2023, then tumbled by 12278.68% to 1643255.85 in 2024, then fell by 25.9% to 2068922.74 in 2025, then grew by 15.09% to 1756650.5 in 2026.
- Business Quant data shows HYFT's Cash from Operations at 1756650.5 in Q2 2026, 2141533.15 in Q1 2026, and 2068922.74 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.76 Mn |
| Apr 30, 2026 | -1.76 Mn |
| Jan 31, 2026 | -2.14 Mn |
| Jan 31, 2026 | -2.14 Mn |
| Oct 31, 2025 | -2.07 Mn |
| Oct 31, 2025 | -2.07 Mn |
| Jul 31, 2025 | -3.07 Mn |
| Jul 31, 2025 | -3.07 Mn |
| Apr 30, 2025 | -801,110.71 |
| Apr 30, 2025 | -801,110.71 |
| Jan 31, 2025 | -847,425.50 |
| Jan 31, 2025 | -847,425.50 |
| Oct 31, 2024 | -1.64 Mn |
| Oct 31, 2024 | -1.64 Mn |
| Jul 31, 2024 | -1.33 Mn |
| Jul 31, 2024 | -1.33 Mn |
| Apr 30, 2024 | -1.17 Mn |
| Apr 30, 2024 | -1.17 Mn |
| Jan 31, 2024 | -763,392.57 |
| Jan 31, 2024 | -763,392.57 |